CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has signed an agreement to sponsor a five-year research program at the Massachusetts Institute of Technology (MIT) Center for Cancer Research focused on the delivery of RNAi therapeutics. Robert Langer, an Institute Professor at MIT and Daniel Anderson, in the MIT Center for Cancer Research, are the co-investigators of the research program and Alnylam will provide research funding for approximately ten post-doctoral researchers annually over the five-year term.
